Cepheid Eyes EUA from FDA for H1N1 Test | GenomeWeb

NEW YORK (GenomeWeb News) – A Cepheid official said yesterday that the firm expects to receive Emergency Use Authorization from the US Food and Drug Administration soon for the firm's molecular test for the 2009 influenza A H1N1 virus.

Cepheid CFO Andrew Miller said yesterday at the UBS Global Life Sciences Conference held here that the firm expects to file for full FDA clearance of the test after it receives the EUA. He said that the test will identify H1, H3, and novel H1N1 strains and will provide results in 45 minutes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.